摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(S)-6-氯-3,4-二氢-2H-噻吩[3,2-E]-1,2-噻嗪-4-醇 1,1-二氧化氮 | 160982-16-1

中文名称
(S)-6-氯-3,4-二氢-2H-噻吩[3,2-E]-1,2-噻嗪-4-醇 1,1-二氧化氮
中文别名
(S)-6-氯-4-羟基-3,4-二氢-2H-噻吩并[3,2-e][1,2]噻嗪1,1-二氧化物;(S)-6-氯-3,4-二氢-2H-噻吩并[3,2-e]-1,2-噻嗪-4-醇1,1-二氧化物;(S)-6-氯-3,4-二氢-2H-噻吩[3,2-E]-1,2-噻嗪-4-醇1,1-二氧化氮
英文名称
(S)-3,4-dihydro-6-chloro-4-hydroxy-4H-thieno[3,2-e]-1,2-thiazine-1,1-dioxide
英文别名
(S)-6-Chloro-3,4-dihydro-4-hydroxy-2H-thieno[3,2-e]-1,2-thiazine 1,1-dioxide;(S)-6-Chloro-4-hydroxy-3,4-dihydro-2H-thieno[3,2-e][1,2]thiazine 1,1-dioxide;(4S)-6-chloro-1,1-dioxo-3,4-dihydro-2H-thieno[3,2-e]thiazin-4-ol
(S)-6-氯-3,4-二氢-2H-噻吩[3,2-E]-1,2-噻嗪-4-醇 1,1-二氧化氮化学式
CAS
160982-16-1;138890-89-8
化学式
C6H6ClNO3S2
mdl
——
分子量
239.704
InChiKey
OFJGKGNJDCLNPM-SCSAIBSYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    128.0 to 132.0 °C
  • 沸点:
    427.9±55.0 °C(Predicted)
  • 密度:
    1.745±0.06 g/cm3(Predicted)
  • 溶解度:
    溶于甲醇

计算性质

  • 辛醇/水分配系数(LogP):
    0.8
  • 重原子数:
    13
  • 可旋转键数:
    0
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.33
  • 拓扑面积:
    103
  • 氢给体数:
    2
  • 氢受体数:
    5

安全信息

  • 海关编码:
    2934999090
  • 危险性防范说明:
    P261,P305+P351+P338
  • 危险性描述:
    H302,H315,H319,H335

SDS

SDS:d730266b4f75a15e11cafe060498e463
查看

上下游信息

反应信息

  • 作为反应物:
    参考文献:
    名称:
    Enantioselective Synthesis of Brinzolamide (AL-4862), a New Topical Carbonic Anhydrase Inhibitor. The “DCAT Route” to Thiophenesulfonamides
    摘要:
    A large scale synthesis of the topical carbonic anhydrase inhibitors AL-4623A (13a . HCl) and AL-4862 (13b) from 3-acetyl-2,5-dichlorothiophene ("DCAT", 1) is described, Reaction of 1 with NaSBn gave thioether 2, which was converted via sulfenyl chloride 3 and sulfenamide 5 to sulfonamide 6, Bromination of 6 gave bromo ketone 7, which upon reduction with (+)-B-chlorodiisopinocampheylborane and cyclization of the resulting bromohydrin produced S thieno[3,2-e]-1,2-thiazine 8a (96% ee) after chromatography, Treatment of 8a in THF with n-BuLi at -70 degrees C resulted in Li-Cl exchange, Reaction of the thienyllithium with SO2 and hydroxylamine O-sulfonic acid afforded bis-sulfonamide 11a, Protection of 11a as the acetinidate 12a, followed by tosylation and amination, gave R amine 13a, The synthesis of 13b proceeded via primary sulfonamide 16, which was brominated, reduced, and cyclized to give S thieno[3,2-e]-1,2-thiazine 18 (>98% ee). By virtue of the ionizable NH, 18 was separable from reduction byproducts by base extraction. Alkylation of 18 with 3-bromopropyl methyl ether afforded 8b, which was converted as above, via 11b, to AL-4862 (13b), These procedures provided multihundred gram lots of 13a and 13b.
    DOI:
    10.1021/op9802125
  • 作为产物:
    描述:
    3-(溴乙酰基)-5-氯-2-噻吩磺酰胺(+)-二异松蒎基氯硼烷 、 sodium hydroxide 作用下, 以 甲基叔丁基醚 为溶剂, 反应 5.5h, 以77%的产率得到(S)-6-氯-3,4-二氢-2H-噻吩[3,2-E]-1,2-噻嗪-4-醇 1,1-二氧化氮
    参考文献:
    名称:
    Enantioselective Synthesis of Brinzolamide (AL-4862), a New Topical Carbonic Anhydrase Inhibitor. The “DCAT Route” to Thiophenesulfonamides
    摘要:
    A large scale synthesis of the topical carbonic anhydrase inhibitors AL-4623A (13a . HCl) and AL-4862 (13b) from 3-acetyl-2,5-dichlorothiophene ("DCAT", 1) is described, Reaction of 1 with NaSBn gave thioether 2, which was converted via sulfenyl chloride 3 and sulfenamide 5 to sulfonamide 6, Bromination of 6 gave bromo ketone 7, which upon reduction with (+)-B-chlorodiisopinocampheylborane and cyclization of the resulting bromohydrin produced S thieno[3,2-e]-1,2-thiazine 8a (96% ee) after chromatography, Treatment of 8a in THF with n-BuLi at -70 degrees C resulted in Li-Cl exchange, Reaction of the thienyllithium with SO2 and hydroxylamine O-sulfonic acid afforded bis-sulfonamide 11a, Protection of 11a as the acetinidate 12a, followed by tosylation and amination, gave R amine 13a, The synthesis of 13b proceeded via primary sulfonamide 16, which was brominated, reduced, and cyclized to give S thieno[3,2-e]-1,2-thiazine 18 (>98% ee). By virtue of the ionizable NH, 18 was separable from reduction byproducts by base extraction. Alkylation of 18 with 3-bromopropyl methyl ether afforded 8b, which was converted as above, via 11b, to AL-4862 (13b), These procedures provided multihundred gram lots of 13a and 13b.
    DOI:
    10.1021/op9802125
  • 作为试剂:
    参考文献:
    名称:
    Preparation of carbonic anhydrase inhibitors
    摘要:
    本发明揭示了一种合成碳酸酐酶抑制剂的方法。
    公开号:
    US05344929A1
点击查看最新优质反应信息

文献信息

  • Sulfonamides useful as carbonic anhydrase inhibitors
    申请人:Alcon Laboratories, Inc.
    公开号:US05378703A1
    公开(公告)日:1995-01-03
    Sulfonamides and pharmaceutical compositions containing the compounds useful in controlling intraocular pressure are disclosed. Methods for controlling intraocular pressure through administration of the compositions are also disclosed.
    磺胺类药物和含有有益于控制眼压的化合物的药物组合物被揭示。还公开了通过给药组合物来控制眼压的方法。
  • Process for the preparation of (R)-(+)-4-(Ethylamino)-3,4-dihydro-2-(3-methoxypropyl)-2H-thieno[3,2-e]-1,2-thiazine-6-sulfonamide-1,1-dioxide.
    申请人:Sathe Dhananjay Govind
    公开号:US20100009977A1
    公开(公告)日:2010-01-14
    Disclosed herein is an improved process for the preparation of (R)-(+)-4-(Ethylamino)-3,4-dihydro-2-(3-methoxypropyl)-2H-thieno[3,2-e]-1,2-thiazine-6-sulfonamide-1,1-dioxide (Brinzolamide) and novel intermediates thereof.
    本文披露了一种改进的工艺,用于制备(R)-(+)-4-(乙基氨基)-3,4-二氢-2-(3-甲氧基丙基)-2H-噻吩[3,2-e]-1,2-噻嗪-6-磺酰胺-1,1-二氧化物(布林唑胺)及其新颖的中间体。
  • HETEROARYLS AND USES THEREOF
    申请人:Freeze Brian S.
    公开号:US20120214794A1
    公开(公告)日:2012-08-23
    This invention provides compounds of formula I-A or I-B: wherein HY, G 1 , G 2 , R 2 , R 12 , W 1 , W 2 , n, and Ring A are as described in the specification. The compounds are inhibitors of PI3K and/or mTor and are thus useful for treating proliferative, inflammatory, or cardiovascular disorders.
    这项发明提供了I-A或I-B式化合物:其中HY、G1、G2、R2、R12、W1、W2、n和环A的定义如规范中所述。这些化合物是PI3K和/或mTor的抑制剂,因此可用于治疗增殖性、炎症性或心血管疾病。
  • Org. Process. Res. Dev. 1999, 3, 114-120
    作者:
    DOI:——
    日期:——
  • US5344929A
    申请人:——
    公开号:US5344929A
    公开(公告)日:1994-09-06
查看更多

同类化合物

布林左胺 布林佐胺盐酸盐 布林佐胺杂质E 布林佐胺杂质C 布林佐胺杂质2 布林佐胺中间体 布林佐胺 布林佐胺 N-去乙基布林佐胺 6-氯-4-羟基-3,4-二氢-2H-噻吩并[3,2-e][1,2]噻嗪1,1-二氧化物 6-氯-2,3-二氢-4H-噻吩并[3,2-e]-1,2-噻嗪-4-酮1,1-二氧化物 6-乙酰基-1H-噻吩并[2,3-b][1,4]噻嗪-2(3H)-酮 4-羟基-2-甲基-2H-噻吩并[2,3-E]-1,2-噻嗪-3-甲酰胺1,1-二氧化物 3,4-二氢-4-羟基-2H-噻吩并[3,2-e]-1,2-噻嗪-1,1-二氧化物 2-(3-甲氧基丙基)-4-氧代-3,4-二氢-2H-噻吩并[3,2-e][1,2]噻嗪-6-磺酰胺1,1-二氧化物 2,3-二氢-4H-噻吩并[2,3-e][1,2]噻嗪-4-酮1,1-二氧化物 1,5,6-三甲基-1,2,3,4-四氢-2LAMBDA6-噻吩并[2,3-C][1,2]噻嗪-2,2,4-三酮 (S)-6-氯-3,4-二氢-2H-噻吩[3,2-E]-1,2-噻嗪-4-醇 1,1-二氧化氮 (S)-6-氯-2-(3-甲氧基丙基)-3,4-二氢-2H-噻吩并[3,2-e][1,2]噻嗪-4-醇 1,1-二氧化物 (S)-3,4-二氢-4-羟基-2-(3-甲氧丙基)-2H-噻吩并[3,2-E]-1,2-噻嗪-6-磺酰胺 1,1-二氧化物 (4S)-3,4-二氢-2-(3-甲氧基丙基)-2H-噻吩并[3,2-e]-1,2-噻嗪-4-醇 1,1-二氧化物 2,3-dihydro-4H-thieno[2,3-e][1,3]thiazine-4-thione 3-(2-isobutylaminoethyl)-2,3-dihydro-4,4-dioxo-6-sulfamoyl-1H-thieno[2,3-b][1,4]thiazine hydrochloride (R)-3,4-dihydro-2-(4-methoxybutyl)-4-propylamino-2H-thieno[3,2-e]-1,2-thiazine-6-sulfonamide-1,1-dioxide (S)-N-(1,1-dimethylethyl)-3,4-dihydro-4-hydroxy-2H-thieno[3,2-e]-1,2-thiazine-6-sulfonamide 1,1-dioxide N-(1,1-dimethylethyl)-2-[4-(4-morpholinyl)-2-butenyl]-2H-thieno[3,2-e]-1,2-thiazine-6-sulfonamide 1,1-dioxide 3,4-Dihydro-4-hydroxy-N-(1,1-dimethylethyl)-2-[4-(4-morpholinyl)-2-butenyl]-2H-thieno[3,2-e]-1,2-thiazine-6-sulfonamide 1,1-dioxide 6-chloro-3,4-dihydro-2-(4-bromobutyl)-2H-thieno[3,2-e]-1,2-thiazine-4-ol 1,1-dioxide 3,4-dihydro-2,6-dimethyl-3-oxo-2H-thieno[3,2-e]-1,2-thiazine-4-carboxanilide 1,1-dioxide (+)-4-Ethylamino-3,4-dihydro-2-methyl-2H-thieno[3,2-e]-1,2-thiazine-6-sulfonamide 1,1-dioxide (+)-4-Hydroxy-2-methyl-2,3-dihydro-4H-thieno[3,2-e]-1,2-thiazine-6-sulfonamide-1,1-dioxide 3,4-Dihydro-2-methyl-2H-thieno[3,2-e]-1,2-thiazine-4-ol-1,1-dioxide 3,4-Dihydro-4-hydroxy-2-(2-methoxy)ethyl-2H-thieno[3,2-e]-1,2-thiazine-6-sulfonamide 1,1-dioxide N-(1,1-Dimethylethyl)-3,4-dihydro-2-(4-methoxybutyl)-4-oxo-2H-thieno[3,2-e]-1,2-thiazine-6-sulfonamide 1,1-dioxide 2,3-Dihydro-N-(1,1-dimethylethyl)-4-oxo-4H-thieno[3,2-e]-1,2-thiazine-6-sulfonamide 1,1-dioxide N-(2-dimethylaminoethyl)-6-ethyl-2,3-dihydro-1H-thieno[2,3-b][1,4]thiazine-1-carboxamide N-(1,1-Dimethylethyl)-3,4-dihydro-4-hydroxy-2-(4-methoxybutyl)-2H-thieno[3,2-e]-1,2-thiazine-6-sulfonamide 1,1-dioxide (S)-N-(1,1-Dimethylethyl)-3,4-dihydro-4-hydroxy-2-(4-methoxybutyl)-2H-thieno[3,2-e]-1,2-thiazine-6-sulfonamide 1,1-dioxide 3,4-Dihydro-3-methyl-2H-thieno[3,2-e]-1,2-thiazine 1,1-dioxide 2-methyl-3,4-dihydro-2H-thieno[2,3-e][1,2]thiazin-4-amine 1,1-dioxide 7-acetyl-1-phenyl-4H-thieno<2,3-b><1,2,4>triazolo<4,3-d><1,4>thiazine T 2097 3-Aethoxycarbonylmethyl-4-hydroxy-2-methyl-2H-thieno<2,3-e>-1,2-thiazin-1,1-dioxid 2-benzylthio-6-ethyl-3H-thieno<2,3-b><1,4>thiazine 2-[(4-methoxyphenyl)methyl]-3-[(4-morpholinyl)methyl]-2H-thieno[3,2-e]-1,2-thiazine 1,1-dioxide 3-[[Bis(2-methoxyethyl)amino]methyl]-2-ethyl-2H-thieno[3,2-e]-1,2-thiazine-6-sulfonamide 1,1-dioxide 3-Hydroxymethyl-2-(1-methylethyl)-2H-thieno[3,2-e]-1,2-thiazine-6-sulfonamide 1,1-dioxide 3-[[(2-methoxyethyl)(3-methoxypropyl)amino]methyl]-2-methyl-2H-thieno[3,2-e]-1,2-thiazine-6-sulfonamide 1,1-dioxide 2-(Cyclopropylmethyl)-3-(4-morpholinylmethyl)-2H-thieno[3,2-e]-1,2-thiazine-6-sulfonamide 1,1 dioxide 3-(4-Morpholinylmethyl)-2-propyl-2H-thieno[3,2-e]-1,2-thiazine-6-sulfonamide 1,1-dioxide